Abstract:The generation of effective levels of antigen-specific immunity at the mucosal sites of pathogen entry is a key goal for vaccinologists. We explored topical vaginal application as an approach to initiate local antigen-specific immunity, enhance previously existing systemic immunity or re-target responses to the mucosae. To deliver a protein vaccine formulation to the vaginal mucosal surface, we used a novel vaginal ring device comprising a silicone elastomer body into which three freeze-dried, rod-shaped, hydroxypropylmethylcellulose inserts were incorporated. Each rod contained recombinant HIV-1 CN54gp140 protein (167μg)±R848 (167μg) adjuvant. The inserts were loaded into cavities within each ring such that only the ends of the inserts were initially exposed. Sheep received a prime-boost vaccination regime comprising intramuscular injection of 100μg CN54gp140+200μg R848 followed by three successive ring applications of one week duration and separated by one month intervals. Other sheep received only the ring devices without intramuscular priming. Serum and vaginal mucosal fluids were sampled every two weeks and analysed by CN54gp140 ELISA and antigen-specific B cells were measured by flow cytometry at necropsy. Vaccine antigen-specific serum antibody responses were detected in both the intramuscularly-primed and vaginal mucosally-primed groups. Those animals that received only vaginal vaccinations had identical IgG but superior IgA responses. Analysis revealed that all animals exhibited mucosal antigen-specific IgG and IgA with the IgA responses 30-fold greater than systemic levels. Importantly, very high numbers of antigen-specific B cells were detected in local genital draining lymph nodes. We have elicited local genital antigen-specific immune responses after topical application of an adjuvanted antigen formulation within a novel vaginal ring vaccine release device. This regimen and delivery method elicited high levels of antigen-specific mucosal IgA and large numbers of local antigen-reactive B cells, both likely essential for effective mucosal protection.

Mucus-penetrating Nonviral Gene Vaccine Processed in the Epithelium for Inducing Advanced Vaginal Mucosal Immune Responses

Engineering intravaginal vaccines to overcome mucosal and epithelial barriers

Nanoparticle-Mediated Mucosal Vaccination: Harnessing Nucleic Acids for Immune Enhancement

Mucosal Vaccine Development Based on Liposome Technology

Local gene expression and immune responses of vaginal DNA vaccination using a needle-free injector

Intravaginal immunisation using a novel antigen-releasing ring device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses

Chitosan-Functionalized Poly(β-Amino Ester) Hybrid System for Gene Delivery in Vaginal Mucosal Epithelial Cells

Injectable Hydrogel Mucosal Vaccine Elicits Protective Immunity against Respiratory Viruses

[Mucosal immunity and vaccines against viral infections]

Mucosal Lactobacillus vectored vaccines.

Adenoviral vectors coated with cationic PEG derivatives for intravaginal vaccination against HIV-1.

DNA Vaccine-Encapsulated Virus-Like Particles Derived from an Orally Transmissible Virus Stimulate Mucosal and Systemic Immune Responses by Oral Administration

Chitosan nanoparticles as gene vector for mucosa vaccination: Preparation, characterization and ability to protect plasmid DNA

Molecular investigations into vaginal immunization with HIV gp41 antigenic construct H4A in a quick release solid dosage form

Recombinant lactic acid bacteria as promising vectors for mucosal vaccination

Mucosal vaccine delivery: A focus on the breakthrough of specific barriers

Mucosal adjuvants

Intravaginal delivery for CRISPR-Cas9 technology: For example, the treatment of HPV infection

Recent progress in application of nanovaccines for enhancing mucosal immune responses

Enhanced Intranasal Delivery of Mrna Vaccine by Overcoming the Nasal Epithelial Barrier Via Intra- and Paracellular Pathways.

Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N.